Laurent Claisse succeeds Joseph Jammal as CEO of Clean Biologics

FRANCE —Clean Biologics, a global provider of services to the biopharmaceutical industry, has named Laurent Claisse as its new Chief Executive Officer.

Claisse steps into the role following the five-year tenure of Joseph Jammal, who is credited with significantly strengthening the group’s operations, particularly at its Clean Cells subsidiary.

 Under Jammal’s leadership, Clean Biologics solidified its reputation as a leading European expert in quality control services for biotherapy developers, advancing its standing in the industry.

Laurent Claisse brings a wealth of international leadership experience, especially from North America-a region where Clean Biologics is actively expanding.

The company recently acquired Karyologic, a North Carolina-based firm located in the state’s renowned life sciences hub.

Before joining Clean Biologics, Claisse served as Senior Vice President of Operations at Sartorius in the Washington DC–Baltimore area.

He has also held senior executive roles at Danaher companies, including Pall Corporation and Molecular Devices.

Expressing his enthusiasm about the new role, Claisse stated, “I’m thrilled to join Clean Biologics at this pivotal moment, especially following its recent strategic acquisition of Karyologic.”

We aim to build on this momentum by further enhancing our presence and capabilities across North America, leveraging the strong foundations already in place.”

His appointment is seen as a strategic move to accelerate Clean Biologics’ growth in the US and globally.

Denis Ribon, managing partner at ARCHIMED-the healthcare-focused private equity firm and majority shareholder of Clean Biologics-welcomed Claisse, highlighting that his extensive international experience in operations, sales, marketing, and business development aligns perfectly with the company’s ambitions.

Ribon also expressed gratitude to Joseph Jammal for his substantial contributions to the group’s growth and welcomed Claisse to further drive the company’s international expansion1.

Reflecting on his time as CEO, Jammal expressed pride in the transformative changes achieved at Clean Biologics.

He described Claisse’s appointment as an exciting new chapter, with a focus on expanding the company’s commercial and strategic reach, particularly in the US market.

This leadership transition marks a strategic pivot for Clean Biologics, positioning the company to refine its commercial approach and strengthen its presence in the promising US market for biotherapies.

In 2024, Clean Biologics reported a turnover of €30 million (approximately US$34 million), with the US accounting for 20% of its revenues.

Clean Biologics offers a range of services to the biopharmaceutical sector, including quality control and manufacturing of biological starting materials-such as cell banks and virus seed stocks-as well as clinical batches of biological drugs.

Its subsidiaries, Clean Cells, Naobios, and Karyologic, provide complementary expertise, specializing in the biological and viral safety of products like recombinant proteins, therapeutic antibodies, viral vaccines, phage therapy, and cell and gene therapies.

Headquartered in Montaigu-Vendée and Saint Herblain near Nantes in western France, Clean Biologics also operates in North America through its subsidiary Karyologic, based in Research Triangle Park, Raleigh-Durham, North Carolina.

The group, established in 2018 with ARCHIMED as a stakeholder, currently employs more than 175 staff worldwide.